NMN & NAD+ HUMAN RESEARCH

NMN is a precursor to NAD+, a molecule involved in fundamental cellular processes. Human research into NMN is still developing, and results vary between studies. Below are selected peer-reviewed human trials exploring oral NMN, NAD-related biomarkers, physical function, metabolic health, sleep and safety.

We present this research for transparency and education. Individual study findings should not be interpreted as guaranteed outcomes from supplementation.

CLINICAL TRIAL 01

NMN, NAD+ levels and physical performance

VIEW ON PUBMED

80 healthy middle-aged adults
Randomised, double-blind, placebo-controlled.

Participants received placebo or 300 mg, 600 mg or 900 mg NMN daily for 60 days. Researchers measured blood NAD-related markers, physical performance and safety.

CLINICAL TRIAL 02

NMN and NAD+ in healthy older men

VIEW ON PUBMED

250 mg daily | Randomised, double-blind, placebo-controlled

This study found that oral NMN increased blood NAD+ and related metabolites in healthy older men. Some physical-function measures were also explored, although the authors noted that findings such as gait and grip performance need confirmation in larger trials. 

CLINICAL TRIAL 03

NAD+, walking and sleep in older adults

VIEW ON PUBMED

Randomised, double-blind, placebo-controlled

Researchers reported increased blood NAD levels and investigated walking speed and sleep quality following NMN supplementation in older adults.

CLINICAL TRIAL 04

NMN, sleep, fatigue and physical performance

VIEW ON PUBMED

108 older adults | 250 mg daily for 12 weeks

This randomised trial examined sleep quality, fatigue and several measures of physical performance. Results differed between measures and timing groups, which makes it a useful example of why the overall evidence needs to be presented with nuance.

CLINICAL TRIALS 05

NMN and metabolic function

VIEW ON PUBMED

Postmenopausal women with prediabetes | Randomised, placebo-controlled

A 10-week trial investigated NMN in overweight or obese postmenopausal women with prediabetes. The researchers reported changes in skeletal-muscle insulin sensitivity and insulin signalling compared with placebo.